-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca Q3 2026 reported EPS rises 23% to $2.02

PUBT·10/30/2026 11:02:01
Listen to the news
AstraZeneca Q3 2026 reported EPS rises 23% to $2.02
  • AstraZeneca's Q3 2026 reported EPS rose 23% to $2.02, while total revenue increased 7% to $16.21 billion.
  • A restructuring program targets $1.5 billion in annualized pretax benefits, with one-time costs of up to $2 billion.
  • Twelve positive Phase III program readouts year-to-date have collective peak-year revenue potential exceeding $10 billion, according to CEO Pascal Soriot.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610300700BIZWIRE_USPR_____20261029_BW477587) on October 30, 2026, and is solely responsible for the information contained therein.